Category: Pα+ - Page 5 - Psychedelic Alpha

Read more about the article Compass Pathways Pushes Back Phase 3 Readouts, Lays Off 30% of Staff

Compass Pathways Pushes Back Phase 3 Readouts, Lays Off 30% of Staff

Post published:October 31, 2024
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #178: VA Funding of Lykos Phase 3 ‘Definitely a Possibility’; Alto’s Precision Psychiatry Platform Under Pressure; MAPS Boosts Funding for Mass. Psychedelics Ballot Question

Pα+ Psychedelic Bulletin #178: VA Funding of Lykos Phase 3 ‘Definitely a Possibility’; Alto’s Precision Psychiatry Platform Under Pressure; MAPS Boosts Funding for Mass. Psychedelics Ballot Question

Post published:October 25, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #177: Bright Minds Surges on Longboard’s Seizure Drug Success; Kasvu Therapeutics Is Developing Psychoplastogens With a TrkB Twist

Pα+ Psychedelic Bulletin #177: Bright Minds Surges on Longboard’s Seizure Drug Success; Kasvu Therapeutics Is Developing Psychoplastogens With a TrkB Twist

Post published:October 18, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #176: Drug Developers Discuss Trial Design; Massachusetts Vote is Too Close to Call as Last-Minute Donations Flow In; SEC Charges ‘Pump and Dump’ Scheme

Pα+ Psychedelic Bulletin #176: Drug Developers Discuss Trial Design; Massachusetts Vote is Too Close to Call as Last-Minute Donations Flow In; SEC Charges ‘Pump and Dump’ Scheme

Post published:October 11, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Psychedelic Funding Update: Q3 2024

Psychedelic Funding Update: Q3 2024

Post published:October 8, 2024
Post category:Analysis Pα+

Read more about the article Pα+ Psychedelic Bulletin #175: atai Sells a Third of Compass Stake; Lykos’ Unproven Psychotherapy Hampered Studies, Claim Academics; Picking Placebos

Pα+ Psychedelic Bulletin #175: atai Sells a Third of Compass Stake; Lykos’ Unproven Psychotherapy Hampered Studies, Claim Academics; Picking Placebos

Post published:October 4, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article The Psychedelics Lobby: Tracking Federal Lobbying by Psychedelics Companies and Nonprofits

The Psychedelics Lobby: Tracking Federal Lobbying by Psychedelics Companies and Nonprofits

Post published:September 30, 2024
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #174: Psilocybin Outperforms Escitalopram After 6 Months… or Does It? Survey Results Reveal Healthcare Practitioner Attitudes to Psychedelics; and more…

Pα+ Psychedelic Bulletin #174: Psilocybin Outperforms Escitalopram After 6 Months… or Does It? Survey Results Reveal Healthcare Practitioner Attitudes to Psychedelics; and more…

Post published:September 27, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #173: Upcoming Trial Readouts to Watch; Lykos Prioritises Preparing for Resubmission Over Formal Dispute

Pα+ Psychedelic Bulletin #173: Upcoming Trial Readouts to Watch; Lykos Prioritises Preparing for Resubmission Over Formal Dispute

Post published:September 20, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Real-World Data Reveals Variability in Access to, and Use of, Spravato

Real-World Data Reveals Variability in Access to, and Use of, Spravato

Post published:September 13, 2024
Post category:Analysis News Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.